These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342 [TBL] [Abstract][Full Text] [Related]
3. Will chemotherapy change the management of prostate cancer? Gilson C; Sydes MR; Chowdhury S BJU Int; 2016 Aug; 118(2):190-2. PubMed ID: 26696125 [No Abstract] [Full Text] [Related]
4. Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED. Aragon-Ching JB Asian J Androl; 2016; 18(3):444-5. PubMed ID: 26510505 [TBL] [Abstract][Full Text] [Related]
6. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. Armstrong AJ Oncology (Williston Park); 2014 Oct; 28(10):881, 883. PubMed ID: 25323615 [No Abstract] [Full Text] [Related]
7. Words of Wisdom. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. Murphy DG; Zargar H Eur Urol; 2016 Mar; 69(3):540. PubMed ID: 26867727 [No Abstract] [Full Text] [Related]
8. Words of Wisdom. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. Mathieu R; Shariat SF Eur Urol; 2016 Apr; 69(4):755-6. PubMed ID: 26972499 [No Abstract] [Full Text] [Related]
9. Abiraterone and increased survival in metastatic prostate cancer. Sonpavde G N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181 [No Abstract] [Full Text] [Related]
10. In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis. Suzman DL; Antonarakis ES Oncology (Williston Park); 2014 Oct; 28(10):880, 882. PubMed ID: 25323614 [No Abstract] [Full Text] [Related]
11. [Comment to: "Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel"]. Angulo JC Actas Urol Esp; 2011 Jan; 35(1):61. PubMed ID: 21322834 [No Abstract] [Full Text] [Related]
12. [Docetaxel for metastatic prostate cancer: early is better]. Gietema JA; Oosting SF Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569 [TBL] [Abstract][Full Text] [Related]
13. Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment. Guancial EA; Taplin ME Clin Genitourin Cancer; 2011 Dec; 9(2):130-2. PubMed ID: 21816687 [No Abstract] [Full Text] [Related]
14. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Armstrong AJ; George DJ Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005 [TBL] [Abstract][Full Text] [Related]
17. Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. Ciccarese C; Santoni M; Massari F N Engl J Med; 2016 Jan; 374(3):286. PubMed ID: 26789884 [No Abstract] [Full Text] [Related]
18. A one-two punch against prostate cancer. Johns Hopkins Med Lett Health After 50; 2014 Mar; 26(1):8. PubMed ID: 24937853 [No Abstract] [Full Text] [Related]